<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1812-9528</journal-id>
<journal-title><![CDATA[Memorias del Instituto de Investigaciones en Ciencias de la Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Mem. Inst. Investig. Cienc. Salud]]></abbrev-journal-title>
<issn>1812-9528</issn>
<publisher>
<publisher-name><![CDATA[Instituto de Investigaciones en Ciencias de la Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1812-95282017000200056</article-id>
<article-id pub-id-type="doi">10.18004/mem.iics/1812-9528/2017.015(02)56-063</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Perfil epidemiológico y retardo en la consulta de pacientes hospitalizados por síndrome coronario agudo]]></article-title>
<article-title xml:lang="en"><![CDATA[Epidemiologic profile and delay to attend hospital of patients with acute coronary syndrome]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Battilana-Dhoedt]]></surname>
<given-names><![CDATA[José Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cáceres-de Italiano]]></surname>
<given-names><![CDATA[Cristina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[Nancy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lovera]]></surname>
<given-names><![CDATA[Oscar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Centurión]]></surname>
<given-names><![CDATA[Osmar Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Asunción Hospital de Clínicas División de Medicina Cardiovascular]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Paraguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2017</year>
</pub-date>
<volume>15</volume>
<numero>2</numero>
<fpage>56</fpage>
<lpage>63</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S1812-95282017000200056&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S1812-95282017000200056&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S1812-95282017000200056&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Las enfermedades cardiovasculares son la primera causa de muerte en el mundo actual. La cardiopatía isquémica conlleva a una importante carga de gastos de Salud Pública, por lo cual es importante conocer la incidencia de pacientes con síndrome coronario agudo (SCA) y su respectivo comportamiento. Este trabajo estudió el tiempo de asistencia al Servicio de Urgencias desde el inicio de la angina de pecho en pacientes con SCA, y evaluó la relación entre factores de riesgo acumulado e incidencia de SCA con elevación del segmento ST (SCACEST). La población de estudio fue de 89 pacientes con SCA, siendo el promedio de edad general de 65 años, el 63% de los pacientes que era del sexo masculino tenía una edad promedio de 61,76 años y el resto del sexo femenino tenía como edad promedio 70,51 años. El 40% de los pacientes presentó SCACEST, el 24% del total de pacientes llegó antes de las 3 horas de iniciados los síntomas lo cual no guardó relación con la procedencia de los mismos. La hipertensión arterial y la diabetes mellitus fueron los factores de riesgo predominantes. Aún permanece alto el porcentaje de pacientes que acuden fuera del periodo terapéutico adecuado (76%), y esta cifra se mantiene sin diferencia significativa si se clasifican de acuerdo a la procedencia. Cada factor de riesgo cardiovascular aumenta la posibilidad de desarrollar un SCACEST a más del 10% en pacientes con SCA.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Cardiovascular diseases are the leading cause of death in the world. Ischemic cardiomyopathy produces an important economic burden to public health. Therefore, it is important to know the incidence of patients with acute coronary syndrome (ACS). This study investigates consultation time at the hospital emergency service from the beginning of symptoms in patients with ACS. In addition, it evaluates the relation between accumulated risk factors and the incidence of ACS with ST segment elevation. The study population comprised 89 patients with ACS with an average of 65 years of age. Sixty three percent of the patients were male and had an average of 61.7 years of age while female population had an average of 70.5 years of age. The percentage of patients with ACS with ST elevation was 40%. Only 24% of the total number of patients arrived within the first 3 hours to the hospital, and it was unrelated to the place where they came from. The predominant risk factors were arterial hypertension and diabetes mellitus. The percentage of people who arrive out of the adequate therapeutic window (76%) still remain high. However, the difference is not statistical significant if it is classified by site of origin. Each of the cardiovascular risk factors increases by 10% the chance of developing ACS with ST elevation in patients with ACS.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[síndrome coronario agudo]]></kwd>
<kwd lng="es"><![CDATA[factores de riesgo cardiovascular]]></kwd>
<kwd lng="es"><![CDATA[retardo en la consulta]]></kwd>
<kwd lng="es"><![CDATA[síndrome coronario agudo con elevación del segmento ST]]></kwd>
<kwd lng="en"><![CDATA[acute coronary syndrome]]></kwd>
<kwd lng="en"><![CDATA[cardiovascular risk factors]]></kwd>
<kwd lng="en"><![CDATA[delay in consultation]]></kwd>
<kwd lng="en"><![CDATA[ST segment elevation acute coronary syndrome]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Acute coronary syndromes in 2011: walking the tightrope between efficacy and bleeding]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kohli]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Rev Cardiol]]></source>
<year>2012</year>
<volume>9</volume>
<page-range>69-71</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mechanisms leading to myocardial infarction: Insights from studies of vascular biology]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fuster]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>1994</year>
<volume>90</volume>
<page-range>2126-46</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Coronary plaque disruption]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Falk]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Fuster]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>1995</year>
<volume>92</volume>
<page-range>657-71</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Frederick]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Stoehr]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Canto]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Ornato]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Gibson]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<source><![CDATA[Am Heart J]]></source>
<year>2008</year>
<volume>156</volume>
<page-range>1026-34</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Heart disease and stroke statistics-2009 update]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lloyd-Jones]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Carnethon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[De Simone]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ferguson]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Flegal]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>2009</year>
<volume>119</volume>
<page-range>480-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[New antiplatelet agents for acute coronary syndromes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferguson]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
</person-group>
<source><![CDATA[Am Heart J]]></source>
<year>1998</year>
<volume>135</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>194-200</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferguson]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Waly]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J]]></source>
<year>1998</year>
<volume>19</volume>
<page-range>3-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Maseri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Armstrong]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Califf]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Gibler]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Hamm]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J]]></source>
<year>1998</year>
<volume>19</volume>
<page-range>D22-30</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST-segment elevation myocardial infarction]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Luca]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Marino]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Thromb Haemost]]></source>
<year>2008</year>
<volume>100</volume>
<page-range>184-95</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Bleeding complications of unfractionated heparin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krishnaswamy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lincoff]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<source><![CDATA[Expert Opin Drug Saf]]></source>
<year>2011</year>
<volume>10</volume>
<page-range>77-84</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tavano]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Visconti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[D&#8217;Andrea]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Focaccio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Golia]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Librera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Cardiol]]></source>
<year>2009</year>
<volume>104</volume>
<page-range>1222-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moliterno]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<collab>TENACITY Steering Committee and Investigators</collab>
<source><![CDATA[Catheter Cardiovasc Interv]]></source>
<year>2011</year>
<volume>77</volume>
<page-range>1001-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tarantini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Brener]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Barioli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gratta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Parodi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rossini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Am Heart J]]></source>
<year>2014</year>
<volume>167</volume>
<page-range>401-12</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[MATRIX investigators. Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX (MATRIX) trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valgimigli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Calabrò]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cortese]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Frigoli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Garducci]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rubartelli]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[J Cardiovasc Transl Res]]></source>
<year>2014</year>
<volume>7</volume>
<page-range>101-11</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Bivalirudin in contemporary PCI for non-ST-segment acute coronary syndromes: what is the current role of platelet glycoprotein IIb/IIIa receptor inhibitor agents?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Centurión]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
</person-group>
<source><![CDATA[Crit Pathw Cardiol]]></source>
<year>2011</year>
<volume>10</volume>
<page-range>87-92</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Actual role of platelet glycoprotein IIb/IIIa receptor inhibitors as adjunctive pharmacological therapy to primary angioplasty in acute myocardial infarction: in the light of recent randomized trials and observational studies with bivalirudin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Centurión]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
</person-group>
<source><![CDATA[Open Cardiovasc Med J]]></source>
<year>2010</year>
<volume>4</volume>
<page-range>135-45</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Heparin versus bivalirudin in contemporary percutaneous coronary intervention: A welcome back to an old friend unfractionated heparin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Centurión]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
</person-group>
<source><![CDATA[Crit Pathways in Cardiol]]></source>
<year>2015</year>
<volume>14</volume>
<page-range>62-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Heparin versus bivalirudin in acute myocardial infarction: Unfractionated heparin monotherapy elevated to primary treatment in contemporary percutaneous coronary intervention]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Centurión]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
</person-group>
<source><![CDATA[The Open Cardiovasc Med J]]></source>
<year>2016</year>
<volume>10</volume>
<page-range>122-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cavender]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Sabatine]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>2014</year>
<volume>384</volume>
<page-range>599-606</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento]]></article-title>
<collab>Grupo de Trabajo para el manejo del síndrome coronario agudo (SCA) en pacientes sin elevación persistente del segmento ST de la Sociedad Europea de Cardiología (ESC)</collab>
<source><![CDATA[T. Rev Esp Cardiol]]></source>
<year>2012</year>
<volume>65</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epidemiología del síndrome coronario agudo y la insuficiencia cardiaca en Latinoamérica]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernandez Leiva]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2011</year>
<volume>64</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>34-43</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Asociación de factores de riesgo cardiovasculares con las diferentes presentaciones del síndrome coronario agudo]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fadine Reis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Brunori]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ruíz]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Cavalcante]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Lat Enferm]]></source>
<year>2014</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>538-46</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Caracterización del síndrome coronario agudo en adultos menores de 45 años de una institución especializada en la Habana, Cuba, entre 2013 y 2014]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valdez Martín]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rivas Estani]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Benítez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chipi Rodríguez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes Navia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Echevarría Sifontes]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Med UIS]]></source>
<year>2015</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>281-90</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epidemiología de la enfermedad cardiovascular en España en los últimos 20 años (I): Epidemiología del síndrome coronario agudo en España: estimación del número de casos y la tendencia de 2005 a 2049]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Degano]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Elosua]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Marrugat]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2013</year>
<volume>66</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>472-81</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cambios en el tratamiento y el pronóstico del síndrome coronario agudo con la implantación del código infarto en un hospital con unidad de hemodinámica]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cordero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Carrillo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Frutos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Miralles]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gunturiz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2016</year>
<volume>69</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>754-9</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guías 2009 de la Sociedad Chilena de Cardiología para el tratamiento del Infarto Agudo del Miocardio con supradesnivel del ST]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guardas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Prieto]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Sanhueza]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dauvergne]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Asenjo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Corbalán]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Chil Cardiol.]]></source>
<year>2009</year>
<volume>28</volume>
<page-range>223-54</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Aptitud clínica en un servicio de urgencias para la atención del paciente con síndrome isquémico coronario agudo]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balcázar-Rincón]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Alcántara]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos-Ortega]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Atención Fam]]></source>
<year>2016</year>
<volume>23</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>150-4</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Evaluación de trombólisis exitosa en el infarto agudo del miocardio por criterios no invasivos de reperfusión]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivas-Hurtado]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Villalobos-Vega]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Mex Cardiol]]></source>
<year>1997</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>85-92</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
